Sage’s oral postpartum depression drug ticks efficacy, safety boxes in key trial, easing fears of fainting risk

Pivotal data on Sage Therapeutics' {$SAGE} keenly-watched oral postpartum depression (PPD) drug showed that there was no loss of consciousness associated with the experimental treatment, unlike the drug developer's brexanolone — which must be administered via an infusion and is currently under FDA review. Late-stage data showed the potential blockbuster drug, SAGE-217, met the primary endpoint, although a serious adverse event was observed in both the drug and placebo arm, the company said on Monday.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->